Blood Based Biomarkers Market To Reach $11.58 Billion By 2030

Blood Based Biomarkers Market Growth & Trends

The global blood based biomarkers market size is expected to reach USD 11.58 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.2% from 2025 to 2030. Rise in the prevalence of chronic diseases along with expanding research and funding drives the blood based biomarkers industry. As the demand for non-invasive diagnostic tools increases, governments, private sectors, and research institutions are prioritizing the funding of studies focused on developing and validating blood-based biomarkers for a wide range of diseases, including cancer, cardiovascular disorders, and neurological conditions. This increased investment enables innovative breakthroughs, enhances the accuracy and reliability of biomarkers, and accelerates the commercialization of new diagnostic tests. Additionally, the growing collaboration between academic institutions, biotechnology companies, and healthcare providers fosters the development of novel technologies, further driving market expansion and improving patient care outcomes.

Technological advancements and launches significantly drives the market, as innovations in high-throughput screening, next-generation sequencing (NGS), and mass spectrometry enhance the sensitivity and precision of biomarker detection. These advancements enable the identification of previously undetectable biomarkers, expanding the range of diseases that can be diagnosed through blood tests. Additionally, the development of microfluidic devices and wearable sensors allows for faster, more cost-effective, and less invasive testing. As technology continues to improve, it enhances the scalability and clinical applicability of blood-based biomarker assays, making them more accessible and valuable for early disease detection, personalized medicine, and monitoring treatment efficacy, thus fueling market growth.

The announcement of Exact Sciences Corp.'s promising performance data for its blood-based colorectal cancer screening test highlights a major advancement for the blood-based biomarker sector: the increasing effectiveness of early detection tests. With sensitivity rates of 88.3% for CRC and 31.2% for advanced precancerous lesions, coupled with a high specificity of 90.1%, the success of such tests reinforces the growing potential of blood-based diagnostics in cancer screening. As more innovative blood-based tests demonstrate high accuracy and reliability, the demand for these non-invasive, early detection solutions is expected to surge, driving further advancements in the market. This progress encourages investment, enhances patient outcomes, and strengthens the adoption of blood-based biomarkers across multiple cancer types.

 Request a free sample copy or view report summary: Blood Based Biomarkers Market Report

Blood Based Biomarkers Market Report Highlights

• In 2024, the genetic biomarkers segment was the largest revenue-generating sector of the blood based biomarkers industry. This is attributed to the growing adoption of genetic biomarkers in blood-based diagnostics is driven by advancements in comprehensive genomic profiling.

• Cancer was the most dominating segment in 2024 due to the consistent research, extensive collaborations among industry leaders to develop blood-based biomarkers for early diagnosis. Increasing cases of cancer and thereby rise in the demand for non invasive methods for diagnosis fuel the segment’s growth.

• Next-Generation Sequencing (NGS) segment dominated the market in 2024 due to the advancements in the technology and rising focus of several key players to develop innovative blood-based biomarkers.

• Hospitals and Clinics segment held the largest share of the end use segment in 2024. This dominance is attributed to the rising prevalence of chronic diseases. As hospitals are center to all the advanced diagnostic services, such as blood-based biomarker testing, patients entrust the established hospitals thus, fueling market growth.

• The North American region is set to reign the global market in the year 2024. The rising implementation of advanced diagnostic tools, increasing wareness, presence of industry leaders in the region and regulatory approvals are anticipated to contribute to the market growth

Blood Based Biomarkers Market Segmentation

Grand View Research has segmented the global blood based biomarkers market on the basis of pet type, application, technology, end use, and region:

Blood Based Biomarkers Type Outlook (Revenue, USD Million, 2024 - 2030)

• Genetic Biomarkers

• Protein Biomarkers

• Metabolic Biomarkers

• Cell-Based Biomarkers

• Epigenetic Biomarkers

Blood Based Biomarkers Application Outlook (Revenue, USD Million, 2024 - 2030)

• Cancer

• Cardiovascular Diseases

• Neurological Diseases

• Immunological Diseases

• Others

Blood Based Biomarkers Technology Outlook (Revenue, USD Million, 2024 - 2030)

• Next-Generation Sequencing

• Polymerase Chain Reaction

• Immunoassays

• Mass Spectrometry

• Others

Blood Based Biomarkers End Use Channel Outlook (Revenue, USD Million, 2024 - 2030)

• Hospitals & Clinics

• Diagnostic Laboratories

• Research & Academic Institutes

• Others

Blood Based Biomarkers Regional Outlook (Revenue, USD Million, 2024 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • Soth Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Blood Based Biomarkers Market

• Abbott

• BIOMÉRIEUX

• F. Hoffmann-La Roche Ltd.

• Siemens Healthineers AG

• Thermo Fisher Scientific, Inc.

• Bio-Rad Laboratories, Inc

• Cleveland Diagnostics, Inc.

• Sysmex Corporation